Drug Information

Drug (ID: DG01366) and It's Reported Resistant Information

• Name: Enfortumab
• Indication:
  In total 2 Indication(s)
  Ureteral cancer [ICD-11: 2C92]; Approved; [1]
  Ureteral cancer [ICD-11: 2C92]; Approved; [1]
• Target: Nectin cell adhesion molecule 4 (NECTIN4); NECT4_HUMAN; [1]
• TTD Drug ID: DORB45

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Ureteral cancer [ICD-11: 2C92]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Nectin cell adhesion molecule 4 (NECTIN4) [1]

• Molecule Alteration: Function; Inhibition
• Sensitive Disease: Advanced urothelial carcinoma [ICD-11: 2C92.Y]
• Experimental Note: Identified from the Human Clinical Data
• Cell Pathway Regulation: Cell growth; Inhibition; hsa05200
• Cell Pathway Regulation: Cell proliferation; Inhibition; hsa05200
• Cell Pathway Regulation: Cell apoptosis; Activation; hsa04210
• Experiment for Drug Resistance: Overall survival analysis; Progression-Free Survival analysis
• Mechanism Description: Nectin-4 is a cell adhesion molecule highly expressed in urothelial carcinoma that may contribute to tumor cell growth and proliferation.Enfortumab vedotin, an antibody-drug conjugate directed against Nectin-4, is comprised of a fully human monoclonal antibody specific for Nectin-4 and monomethyl auristatin E, a microtubule-disrupting agent.

References

• Ref 1: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma .N Engl J Med. 2021 Mar 25;384(12):1125-1135. doi: 10.1056/NEJMoa2035807. Epub 2021 Feb 12. 10.1056/NEJMoa2035807